CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2017 EMUC Congress
Oncology Conference Multimedia
View more videos >>
Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer
Dr. Powles on the Impact of Immunotherapy in Kidney Cancer
Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC Treatment
Oncology Conference Articles
Optimizing Adjuvant Therapy in Renal Cell Carcinoma
Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.
Immunotherapy Continues to Shape Future Bladder Cancer Paradigm
Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.
Next Steps in Bladder Cancer to Include Combination Immunotherapy
Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.
Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC
Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.
LDH a Predictor for OS in mCRPC Following Radium-223
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC
An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.
Pembrolizumab, Atezolizumab New Standards for Bladder Cancer
A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.
Combining Partial Metastasectomy With Systemic Treatment Beneficial in mRCC
The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.
PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy
Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.
FDA Approvals in Breast Cancer and Prostate Cancer, Priority Review in Breast Cancer, and More
Lonial Lays Out Optimal Sequence Strategies for Relapsed/Refractory Myeloma
FDA Approves Ivosidenib for IDH1+ AML
Immunotherapy Treatment Options Continue to Grow in Relapsed/Refractory Multiple Myeloma
Expert Shares Insights on CLL Treatment Paradigm
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.